Neurostimulator to repair myelin in RRMS named breakthrough device
The U.S. Food and Drug Administration has designated SetPoint Medicalās neurostimulator a breakthrough device for the treatment of relapsing-remitting multiple sclerosis (RRMS). This designation is intended to accelerate the development of devices intending to more effectively treat or diagnose life-threatening or chronically debilitating diseases than standard approaches.